Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gentamicin
Drug ID BADD_D01016
Description Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963.[A234349] It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by _Pseudomonas aeruginosa_.[A233325,A234359,A234364] There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams.[A234364] This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.[A234359,A234364] Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.[A234369]
Indications and Usage For treatment of serious infections caused by susceptible strains of the following microorganisms: P. aeruginosa, Proteus species (indole-positive and indole-negative), E. coli, Klebsiella-Enterobactor-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative).
Marketing Status Prescription; Discontinued
ATC Code D06AX07; J01GB03; S01AA11; S02AA14; S03AA06
DrugBank ID DB00798
KEGG ID D08013
MeSH ID D005839
PubChem ID 3467
TTD Drug ID D0L9UU
NDC Product Code 51662-1508; 63323-173
Synonyms Gentamicins | Gentamycins | Garamycin | Gentacycol | Gentamicin Sulfate | Sulfate, Gentamicin | Gentamicin Sulfate (USP) | Gentavet | Genticin | G-Myticin | G Myticin | GMyticin | Gentamicin | Gentamycin
Chemical Information
Molecular Formula C21H43N5O7
CAS Registry Number 1403-66-3
SMILES CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
NecrosisSodium/potassium-transporting ATPase subunit alpha-1P05023T408001647125; 1322021; 12905033; 2843053; 1315476; 2563204; 7694338; 11832431
Nephropathy toxicVariant-surface-glycoprotein phospholipase CP09194Not Available6092605; 6307156; 6276533; 3566282; 8663028; 3164751; 2623196; 7876334; 2159723; 8498544; 12039977
Renal impairmentLysosomal Pro-X carboxypeptidaseP42785T20371Not Available
Renal impairmentDipeptidyl aminopeptidase-like protein 6P42658Not AvailableNot Available
Toxicity to various agentsPhospholipase A2P04054T31479Not Available
Toxicity to various agents1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1Q9NQ66T26846Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Noninfectious peritonitis07.07.01.0050.001377%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.005508%Not Available
Candida infection11.03.03.0210.001377%
Multiple organ dysfunction syndrome08.01.03.0570.000539%
Respiratory rate increased13.15.01.0040.001377%Not Available
Bradycardia neonatal18.04.07.004; 02.03.02.0190.001377%Not Available
Embolia cutis medicamentosa08.02.03.052; 24.01.01.030; 12.07.03.0520.002065%Not Available
Antibiotic level above therapeutic13.17.01.0150.001377%Not Available
Mycobacterium abscessus infection11.04.02.0040.005508%Not Available
Toxic anterior segment syndrome12.02.02.010; 06.04.10.0060.004131%Not Available
Quality of life decreased13.18.01.0130.001377%Not Available
Heart valve incompetence02.07.02.0030.001377%Not Available
Myeloma cast nephropathy20.05.03.018; 16.32.03.0240.000718%Not Available
The 8th Page    First    Pre   8    Total 8 Pages